OnThePharm thinks so. The GLP-1 based therapies are an exciting new class of diabetes medications. So far, Byetta has worked well for my patients – the jury is still out with Januvia. Merck certainly hopes that Januvia will rescue them.
Will Januvia take out Byetta?
More in Uncategorized
Past Week
Past 6 Months
-
Medicine’s struggle for inclusivity
-
Medicine is not apolitical: Your vote dictates your ability to practice medicine
-
Venture-backed telemental health care companies are creating a new opioid epidemic
-
Elite access vs. public scrutiny: Medication disparities exposed
-
How Enhanced Recovery After Surgery solves our opioid problems
-
Real pain deserves real treatment
-
Recent Posts
Subscribe to KevinMD and never miss a story!
Get free updates delivered free to your inbox.
